{
    "nctId": "NCT00433095",
    "briefTitle": "Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer",
    "officialTitle": "N/A",
    "overallStatus": "COMPLETED",
    "conditions": "Carcinoma Breast Stage IV",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": "N/A",
    "primaryOutcomeMeasure": "Response rate",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically proven, metastatic breats cancer.\n* HER2-neu overexpression (IHC3+ or IHC2+/FISH+)\n* Written informed consent\n* no previous therapy with vinorelbine or trastuzumab\n* Age \\* 18 and \\* 75 years\n* Karnofsky-Performance status \\> 70%\n* Life expectance 16 weeks and more\n* Availability of at least one target lesion according to RECIST-criteria. Target lesions need to be outside of radiation fields. Bone metastases are excluded as indicator leasions\n* Exclusion of pregnancy and adequte contraception during childbearing age.\n\n  * Adequate hematological, renal, and hepatic function\n* Normal cardiac function. LVEF should not be \\>10% below normal.\n* Adequate compliance to perform treatment and subsequent follow-up visits\n\nExclusion Criteria:\n\n* Locoregional recurrence of breast cancer only or development of contralateral breast cancer\n* Pregnancy or lactation\n* Symptomatic brain- or meningeal metastasis\n* Concurrent endocrine antitumor therapy\n* Other malignancies except basal cell cancer of the skin or in-situ carcinoma of the cervix\n* Peripheral neuropathy \\>= NCI CTC Grade 2.\n* other severel disease which preclude adequate treatment\n* Participation in a clinical trial within the last 30 days.\n* Psychological, familial, sociological or geographical conditions which preclude treatment according to the protocol or the planned follow-up",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}